A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience
Background/AimsThe widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested tha...
Main Authors: | Myung Jin Oh, Heon Ju Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2013-03-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-19-51.pdf |
Similar Items
-
Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report
by: Nicholas Brousseau, et al.
Published: (2017-04-01) -
Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglubulinemia
by: José Ignacio Fortea Ormaechea, et al.
Published: (2013-09-01) -
A Case of Autoimmune Hepatitis Treated with Rituximab
by: E. Barth, et al.
Published: (2010-11-01) -
Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
by: Hee Kyung Kim, et al.
Published: (2020-01-01) -
Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab
by: Dae San Yoo, MD, et al.
Published: (2020-02-01)